With the emergence of multidrug resistant Salmonella strains, the development of anti-Salmonella vaccines is an important task. Currently there are no approved vaccines against Salmonella Paratyphi A, the leading cause of paratyphoid fever.T of ill this gap, oligosaccharides corresponding to the O-polysaccharider epeating units from the surface of Salmonella Paratyphi Ah ave been synthesizedt hrough convergents tereoselective glycosylations.T he synthetic glycan antigenwas conjugatedw ith ap owerful immunogenic carrier system, the bacteriophage Qb.T he resulting construct was able to elicit stronga nd long-lasting anti-glycan IgG an-tibodyr esponses, which wereh ighly selectivetoward Salmonella Paratyphi Aa ssociated glycans. The availability of welldefined glycana ntigen enabledt he determinationt hat one repeating unit of the polysaccharide is sufficient to induce protectivea ntibodies, and the paratose residue and/ort he O-acetyl modificationso nt he backbonea re important for recognition by antibodies elicited by aQ b-tetrasaccharide conjugate. Immune sera provided excellentp rotection to mice from lethal challenge with Salmonella Paratyphi A, highlighting the potentialo ft he synthetic glycan-based vaccine.